The effect of chlorpyrifos oral exposure on the histomorphometric and kidney function in Wistar rat.

BACKGROUND: Chlorpyrifos belongs to a broad-spectrum organophosphate insecticide that has high toxicity, is metabolized in the liver by the oxidation reaction, and can inhibit acetylcholinesterase activity. Acetylcholinesterase inhibition generates the reactive oxygen species and induces oxidative stress, which ultimately results in cellular damage like in the kidney. Examining blood urea nitrogen (BUN) levels, creatinine, and kidney histopathology is an appropriate indicator to assess the toxicity of chlorpyrifos to the degree of damage to cells and kidney tissue. MATERIALS AND METHODS: This research used to determine the effect of duration of exposure to chlorpyrifos and dose-response relationships is important for early detection of the effects of chlorpyrifos toxicity on health. The research study was a true experimental (completely randomized design) consisting of 30 subjects divided into 5 groups. Controlled Group (K1) given 1 mg/kg BW Tween 20 and NaCl 0, 9% until the 56th day. The chlorpyrifos exposed group (P1, P2, P3, and P4) was given chlorpyrifos 5 mg/kg BW for 7, 14, 28, and 56 days. After the treatment, BUN and creatinine levels were measured, and microscopic changes in the kidney were analyzed. The results of BUN, creatinine, and kidney histopathologic were analyzed using the analysis of variance statistical test. RESULTS: The data result showed that compared to the control group, there were significant increases of BUN and creatinine (P = 0.013 and P = 0.003). Histopathological examinations of kidney glomerulus diameter were also smaller compared to the control group (P = 0.00). All the data measurement indicates significant differences compared to the control group. CONCLUSIONS: We concluded that sub-chronic oral exposure to chlorpyrifos at low doses can damage the kidneys and cause kidney failure.

COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia.

INTRODUCTION: Coronavirus Disease (COVID-19) caused by Novel Coronavirus named as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was declared Pandemic by The World Health Organization (WHO) and a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. Many COVID-19 vaccines have been developed, including CoronaVac vaccines by Sinovac. Health care workers, along with medical clerkship students are the priority to receive the vaccine. However, the Adverse Events Following Immunization (AEFI) of the CoronaVac remains unclear. This study aims to describe and analyze the adverse events following immunization (AEFI) of COVID-19 vaccination in medical students in clerkship programs. METHOD: We conducted a cross-sectional study using a questionnaire to assess AEFI after CoronaVac vaccination among medical clerkship students. A Chi-Square test with 95 % of CI was used to determine whether gender correlated with symptoms of AEFI. RESULT: We identified 144 medical clerkship students. The most common AEFI of SARS-CoV-2 vaccinations was localized pain in the injection site during the first dose with 25 (45 %) reports and the booster dose with 34 (67 %) reports. Then followed by malaise, the first dose with 20 (36 %) reports and the booster dose with 21 (41 %) reports. Other symptoms like headache, fever, shivering, sleepiness, nausea, dysphagia, and cold were also reported. CONCLUSIONS: CoronaVac SARS-COV-2 vaccine has several mild symptoms of AEFI and not correlated with gender. Nevertheless, follow-up after vaccination is needed to prevent immunologic responses that may occur in some patients.

Gel formulations of Merremia mammosa (Lour.) accelerated wound healing of the wound in diabetic rats.

BACKGROUND AND AIM: The treatment of diabetic ulcers is difficult because of defective blood vessels and frequent co-occurrence of bacterial infections. In a previous study, we found a water fraction of Merremia mammosa (Lour.) (Mm(Lour.)) had beneficial effects on wound healing in diabetic rats. This study aimed to evaluate the influence of different gelling agents added to Mm(Lour.) water fraction gel on wound healing treatment in diabetic rats. EXPERIMENTAL PROCEDURE: Diabetic Wistar rats were divided into the following five groups: 1. positive control (Neomycin Sulfate 0.5% and Placenta Extract 10%), 2. negative control (distilled water), and 10% water fraction of Mm(Lour.) extract in 3. HPMC, 4. Carbopol, and 5. CMC Na gelling agents. The wound was made by the Morton method and treatment applied every other day for 25 days, then the wound healing process was observed. Data were observed and analysed using appropriate statistic tools. RESULTS: Histopathology observation, VEGF expression and hydroxyproline levels showed a significant acceleration of wound healing in all treatment groups compared to the negative control group. This study showed all of Mm(Lour.) gel formulations could restore the delayed healing process on wound in diabetic rats and were equally effective in accelerating wound healing. CMC Na was the most preferable because it did not irritate. CONCLUSION: The results suggest that Mm(Lour.) water fraction in CMC Na gelling agent provided an option to be developed as a topical drug on diabetic wound healing treatment, showed by enhancement of collagen synthesis and angiogenesis.